热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 美股周三个别发展，美国私人机构职位增长逊预期，大市破顶后反复倒跌，三大指数收市升跌不一。美 元走势向好，美国十年期债息回落至4.15厘水平，金价表现受压，油价走势向下。 客户端 美股周三个别发展，美国私人机构职位增长逊预期，大市破顶后反复倒跌，三大指数收市升跌不一。美 元走势向好，美国十年期债息回落至4.15厘水平，金价表现受压，油价走势向下。 今日港股三大指数集体低开，恒指开盘跌0.59%，报26302.78点，恒科指跌0.44%，国企指数跌0.43%。 盘面上，科网股普跌，百度、阿里巴巴跌超1%；创新药概念延续涨势，先声药业涨超1%；锂电池股活 跃，宁德时代涨近1%；石油股走弱，上海石油化工跌超1%；今日3只新股上市，智谱涨超3%，天数智 芯涨超31%，精锋医疗-B涨超36%。 | 名称 | 最新价 | 涨跌幅 へ | | --- | --- | --- | | 恒生指数 | 26302.78 | -0.59% | | 800000 | | | | 恒生科技指数 | 5713.53 | -0.44% | | 800700 | | | | 国企指数 ...

1月7日，A股三大指数再度集体上涨。截至1月7日收盘，上证指数收涨0.05%，报4085.77点， 盘中一度触及4098.78点，达到2015年以来的新高，意味着A股上涨行情从2025年向2026年顺 利延续。 此轮上涨行情起于2024年9月底中央出台的一系列增量政策提振市场信心，随后的2025年春 节，"DeepSeek时刻"点燃了A股行情，全球投资者开始关注到中国在科技领域发展的超预期发 展，从而推动了中国资产重估。 科技股成为推动A股本轮行情的结构性的支柱力量。 从行业来看，2025年8月电子行业市值首 次超过银行业，成为股票市场第一大行业。市场整体"含科量"超过25%，从全年涨幅看，创业 板指上涨49.57%，科创50上涨35.92%，北证50上涨38.81%，均高于上证指数、深证成指。 2026年元旦假期以来连续三个交易日的上涨，也主要是由科技股推动。 2026年，随着中国企 业在半导体、创新药等领域以及其他新兴产业的快速发展，科技类上市公司将继续成为A股上 涨行情的内在强大驱动力。 推动A股上涨的另一大因素是不断完善的市场监管体系以及政策支持。 自2023年开始，中国更 加重视活跃资本市场与提振市 ...

行业多项关键政策突破与落地，首版《商业健康保险创新药品目录》于2025年12月正式发布，其构建 的"基本医保保基本，商保保创新"的多层次支付体系，为高值创新药开辟出市场新通路。 展望2026年，业内人士普遍看好，在产业政策对真创新、高水平创新的支持下，大量创新药BD将密集 落地。 商保实施与集采优化双轮推动下，创新药产业链高景气度有望延续，高价值创新药有望迎来第二增长曲 线。 港股创新药板块企业包括： 智通财经APP获悉，记者从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临 床用药迫切需求，国家药监局进一步优化这类药品审评审批。国家药监局表示，坚持以临床价值为导 向，鼓励申请人在中国开展全球同步研发、同步申报上市;鼓励临床急需境外已上市的原研药及仿制药 在境内申报，对于符合要求的可纳入优先审评审批范围。 公告显示，国家药监局将优化审评机制，加快审评速度;同时，也将完善检验制度，体现品种特点。 2025年我国已批准上市的创新药达76个，大幅超过2024年全年48个，创历史新高。此外，2025年我国创 新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，同样创历史新高。 据了解 ...

Core Viewpoint - The A-share market has shown strength in early 2026, with significant gains in the semiconductor and non-ferrous sectors, while the previously quiet innovative drug sector has also regained attention, particularly in the Hong Kong market [1][8]. Group 1: Innovative Drug Sector Recovery - Several ETFs related to innovative drugs have seen substantial gains, with five funds increasing over 7% in just three days, and others tracking A-shares also showing over 5% growth [2][9]. - After a downturn in the fourth quarter of 2025, many fund managers believe that the current valuation of the innovative drug sector is attractive, suggesting that 2026 may be a good time to invest in pharmaceuticals [2][10]. - The innovative drug sector is expected to remain a key investment theme in 2026, with positive catalysts emerging from industry events and improved overseas liquidity conditions [10][11]. Group 2: Market Trends and Individual Stock Selection - The consensus among fund managers indicates that a broad market rally is unlikely to repeat, with a focus on high-quality assets that can sustain independent performance [3][10]. - The "outbound" capability of companies is becoming a critical factor in stock selection, with a focus on those that can effectively commercialize their products internationally [6][12]. - Fund managers emphasize the importance of companies with strong execution capabilities in the innovative drug sector, particularly those that can leverage partnerships for international clinical trials and market entry [12][13]. Group 3: Brain-Computer Interface and Medical Devices - The brain-computer interface (BCI) concept has gained traction, with expectations for commercialization in 2026, driven by advancements from companies like Neuralink [4][11]. - The medical device sector is seen as a primary application area for BCI technology, with potential benefits for patients with disabilities [4][11]. - The industry is expected to experience growth due to innovation and government support, with domestic leaders in high-end equipment continuing to gain market share [4][11].

Group 1 - The Macau Drug Regulatory Authority (ISAF) has approved the listing of Chidamide (brand name "Epidaza") by Shenzhen MicuRx Biopharma Co., Ltd [2] - Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and has been granted multiple indications in different regions, including peripheral T-cell lymphoma and breast cancer in mainland China, and adult leukemia and peripheral T-cell lymphoma in Japan [2] - The approval in Macau allows the company to expand its overseas market presence and enhance the market competitiveness of Chidamide [3]

Core Viewpoint - The A-share market is experiencing a historic moment with the Shanghai Composite Index recording a 14-day winning streak, while the Hong Kong market shows weakness, particularly in technology stocks. However, innovative drug ETFs are performing well, indicating strong investor interest in the healthcare sector [1][3][4]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has risen over 3%, marking three consecutive days of gains, while the overall market shows mixed results. The Pharmaceutical ETF (562050) also recorded three consecutive daily gains, indicating a strong performance in the pharmaceutical sector [1][3][4]. - The largest medical ETF in the market (512170) is approaching its six-month line, reaching a new 20-day high, reflecting positive momentum in the healthcare sector [1][3][4]. Sector Highlights - The pharmaceutical sector is significantly outperforming the broader market, with leading innovative drug companies like Rongchang Bio surging over 11%. The overall performance of the pharmaceutical ETF indicates a strong bullish sentiment among investors [3][4]. - The AI application sector is also gaining traction, with the Entrepreneurial Board AI ETF (159363) reaching a new high, supported by strong performance in AI hardware and applications [9][11]. Market Outlook - Huaxi Securities suggests that the current market dynamics indicate an early spring rally, maintaining a bullish outlook. Key investment themes include emerging growth sectors and opportunities arising from anti-involution trends, particularly in AI, robotics, and renewable energy [2][20]. - The outlook for the metals sector remains optimistic, driven by macroeconomic factors such as potential interest rate cuts by the Federal Reserve and strong demand in traditional and emerging industries [13][15]. Investment Recommendations - Analysts recommend focusing on sectors benefiting from policy support, such as AI computing chains, robotics, and domestic replacements, as well as sectors poised for price increases like chemicals and non-ferrous metals [2][20]. - The innovative drug and medical device sectors are highlighted as key areas for investment, with a focus on companies that are expected to maintain strong growth trajectories through 2026 [7][20].

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

Market Overview - A-shares experienced a historic moment with the Shanghai Composite Index recording a 14-day winning streak, while the ChiNext Index fluctuated before closing lower. The total trading volume exceeded 28 trillion yuan over two consecutive trading days [1][19]. - The Hong Kong stock market showed weakness, with the Hang Seng Index down 0.94% and the Hang Seng Tech Index down 1.49%. However, the Hong Kong Stock Connect innovative drug sector performed well [1][19]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) rose over 3%, marking its third consecutive increase, while the only ETF representing the pharmaceutical sector (562050) also recorded three consecutive days of gains. The largest medical ETF (512170) approached its six-month high [1][3][21]. - The Entrepreneurial Board Artificial Intelligence ETF (159363) increased by 0.79%, reaching a new high, while the broad-based dual-innovation leader ETF (588330) aimed for previous highs [1][3][19]. Pharmaceutical Sector - The pharmaceutical sector outperformed the broader market, with the innovative drug leader Rongchang Bio surging over 11%. The medical ETF (562050) achieved three consecutive daily gains [3][21]. - The medical sector showed some differentiation, with the brain-computer interface concept remaining popular. The largest medical ETF (512170) continued to rise, reaching a new 20-day high [3][21]. AI and Technology Sector - The Entrepreneurial Board Artificial Intelligence Index reached a new high, driven by strong performances in computing hardware and AI applications. Notable stocks included Zhishang Technology, which rose over 7%, and several others that increased by over 3% [25][27]. - The upcoming launch of DeepSeek's flagship system R2 is expected to catalyze AI applications, with Meta's acquisition of Manus further enhancing AI capabilities [27][28]. Rare Earth and Nonferrous Metals - The nonferrous metals ETF (159876) saw a significant increase, with a net subscription of 54.6 million units, reflecting strong investor interest. The ETF's price rose by over 1.6% during the day [10][12]. - The nonferrous metals market is experiencing a bullish trend due to various factors, including supply constraints and increased demand from new industries [10][13].

Group 1 - The Hong Kong innovative drug sector has recorded a three-day consecutive rise since the beginning of 2025, with a rebound of approximately 10% in the main innovative drug index [1][3] - The Hong Kong innovative drug ETF (520880) has accumulated a gain of 9.24% since the start of the year, with a daily increase of over 3.4% [1] - In 2025, the Hong Kong innovative drug sector has shown an overall increase of over 60%, becoming a significant player in the market, despite experiencing a notable pullback in Q4 [3][4] Group 2 - The innovative drug sector's strong performance in early 2025 is attributed to favorable policies, exceeding industry data expectations, and the approach of significant industry conferences [6] - The total amount of outbound licensing for Chinese innovative drugs reached $135.655 billion in 2025, with 157 transactions, both setting historical records [6] - The number of new drug pipelines under research in China accounts for 30% of the global total, ranking second worldwide [6] Group 3 - Investment outlook for 2026 focuses on innovation and international expansion, with an emphasis on companies that have achieved significant business development transactions and overseas clinical progress [7] - The innovative drug industry is entering a "dual-driven" phase of product development and commercial sales, highlighting the importance of next-generation therapies such as ADCs and dual antibodies [7] - The AI pharmaceutical sector and brain-computer interfaces are expected to accelerate industrialization due to clear policy development paths and insurance pricing support [8] Group 4 - The investment logic in the pharmaceutical sector for 2026 has shifted from broad market increases to selective alpha investments, favoring companies with strong technology and clear commercialization paths [8] - Relevant ETFs include the Hong Kong innovative drug ETF (520880), drug ETF (562050), and medical ETF (512170) [8]

Group 1 - The core viewpoint of the article highlights the strong performance of Hong Kong innovative drug stocks, particularly WuXi AppTec (2268.HK), which rose by 5.5% to HKD 68.75, marking its fourth consecutive day of increase [1] - Other notable performers include Sangamo Therapeutics, which increased by over 7%, WuXi Biologics rising by over 6%, Innovent Biologics up nearly 6%, and WuXi AppTec gaining nearly 5%, all achieving four consecutive days of growth [1] - According to a report by CMB International published in December, the trend of innovative drugs going overseas is expected to continue into 2026, with a focus on the clinical progress and data validation of pipelines that have already entered international markets [1] Group 2 - The article mentions that the recently enacted U.S. Biosecurity Act is not expected to significantly impact the operations of Chinese CXO companies, as it does not affect Medicaid and Medicare procurement and has clear definitions regarding related parties [1] - CMB International's industry outlook suggests a more conservative investment approach, emphasizing opportunities in undervalued stocks, and recommends buying Sangamo Therapeutics, Genscript Biotech, WuXi AppTec, and China National Pharmaceutical Group [1]